EDN1 is well known to support tumour growth and progression through acting on the microenvironment (Rosano et al, 2013), and hence, interfering with EDNR signalling apart from targeting melanoma cell phenotypes could have the additional benefit of suppressing a favourable tumour microenvironment. The gene discussed is EDN1; the disease is neoplasm.